(-)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds inducing the formation of morphologically similar tubulin spirals but binding apparently to two distinct sites on tubulin.
The most potent microtubule assembly inhibitor of newer diphenylpyridazinone derivatives examined was NSC 613241. Because NSC 613241 and (-)-rhazinilam also induce the formation of similar 2-filament spirals, these aberrant reactions were compared. Spiral formation with both compounds was enhanced by GTP and inhibited by GDP and by 15 other inhibitors of microtubule assembly. Similarly, microtubule assembly induced by paclitaxel or laulimalide is enhanced by GTP and inhibited by GDP and assembly inhibitors, but neither [(3)H]NSC 613241 nor [(3)H](-)-rhazinilam bound to microtubules or inhibited the binding of [(3)H]paclitaxel or [(3)H]peloruside A to microtubules. Differences in the pitch of aberrant polymers were found: NSC 613241-induced and (-)-rhazinilam-induced spirals had average repeats of 85 and 79-80 nm, respectively. We found no binding of [(3)H]NSC 613241 or [(3)H](-)-rhazinilam to αβ-tubulin dimer, but both compounds were incorporated into the polymers they induced in substoichiometric reactions, with as little as 0.1-0.2 mol compound/mol of tubulin, and no cross-inhibition by NSC 613241 or (-)-rhazinilam into spirals occurred. Under reaction conditions where neither compound induced spiral formation, both compounds together synergistically induced substantial spiral formation. We conclude that (-)-rhazinilam and NSC 613241 bind to different sites on tubulin that differ from binding sites for other antitubulin agents.
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, MD 21702, USA.
Ruoli
R
Bai
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, MD 21702, USA. Electronic address: hamele@mail.nih.gov.
Ernest
E
Hamel
D000470:Alkaloids / Q000737:chemistry*; D001665:Binding Sites; D004305:Dose-Response Relationship, Drug; D018698:Glutamic Acid / Q000737:chemistry; D006153:Guanosine Diphosphate / Q000737:chemistry; D006160:Guanosine Triphosphate / Q000737:chemistry; D006801:Humans; D007212:Indolizines / Q000737:chemistry; D007769:Lactams / Q000737:chemistry; D008024:Ligands; D008854:Microscopy, Electron; D011485:Protein Binding; D011724:Pyridazines / Q000737:chemistry*; D011725:Pyridines / Q000737:chemistry*; D013237:Stereoisomerism; D013696:Temperature; D014404:Tubulin / Q000737:chemistry*
D000470:Alkaloids; D007212:Indolizines; D007769:Lactams; D008024:Ligands; C000618347:NSC 613241; D011724:Pyridazines; D011725:Pyridines; D014404:Tubulin; D006153:Guanosine Diphosphate; C009170:rhazinilam; D018698:Glutamic Acid; D006160:Guanosine Triphosphate
(−)-Rhazinilam; 4-morpholineethanesulfonate; DPP; Diphenylpyridazinone derivatives; Glutaraldehyde-fixed microtubules; HPLC; Inhibition of tubulin assembly; MAPs; Mes; NSC 613241; Tubulin polymer of aberrant morphology; diphenylpyridazinone; gMTs; glutaraldehyde-fixed microtubules; high-performance liquid chromatography; microtubule-associated proteins